Per Svenningsson´s research group
Parkinson's disease (PD) is a common disease in which the basic pathophysiology is unclear. The next breakthrough in the treatment of PD should delay disease progression, based on insights into the underlying pathogenic process. The development of disease-modifying drugs is hampered by the lack of adequate diagnostics and biomarkers that reflect early signs of the disease. The classic motor signs of PD are often preceded by non-motor symptoms such as depression, hyposmia, REM sleep disturbance and / or constipation.
It is important to develop an improved knowledge of these clinical signs of early PD as neuroprotective and reparative therapy for PD should preferably be offered at an early stage to effectively change the course of the disease. In the laboratory, cell and animal models are developed to mimic the progressive disease progression in PD. Biochemical, histological, pharmacological, molecular biology and behavioral techniques are used in these studies.
In clinical trials with patients, clinical estimates, biochemical and imaging (PET and MRI) analyzes are performed. A special emphasis is placed on non-motor symptoms in PD and the identification of biomarkers. The information is transferred to a newly developed PD quality register. The research group also studies unipolar depression in both animal models and patient samples. In addition to PD, other movement disorders are also studied, especially Huntington's disease and ataxias.
- Receptor dynamics in neurons. Focus on adapter proteins and lipid aggregates
- Studies of progressive Parkinsonism
- Studies of depression in Parkinson's disease
- Identification of clinical biomarkers in different forms of Parkinsonism
- Clinical trials with 5-HT1A / B receptor agonists against L-DOPA-induced dyskinesia in patients with advanced Parkinson's disease
- Research on the interactive effects of genetic variants, epigenetics and gene expression on disease progression in Parkinson's and Huntington's disease
- Pre-clinical mechanistic studies of substances with potential for testing in clinical trials in Parkinson's and Huntington's disease.
For more information about our research, please visit our external website.
Emotional memory impairments in a genetic rat model of depression: involvement of 5-HT/MEK/Arc signaling in restoration.
Eriksson TM, Delagrange P, Spedding M, Popoli M, Mathé AA, Ögren SO, et al
Mol. Psychiatry 2012 Feb;17(2):173-84
Coupling surface plasmon resonance to mass spectrometry to discover novel protein-protein interactions.
Madeira A, Ohman E, Nilsson A, Sjögren B, Andrén PE, Svenningsson P
Nat Protoc 2009 ;4(7):1023-37
Evidence for a role of the 5-HT1B receptor and its adaptor protein, p11, in L-DOPA treatment of an animal model of Parkinsonism.
Zhang X, Andren PE, Greengard P, Svenningsson P
Proc. Natl. Acad. Sci. U.S.A. 2008 Feb;105(6):2163-8
Alterations in 5-HT1B receptor function by p11 in depression-like states.
Svenningsson P, Chergui K, Rachleff I, Flajolet M, Zhang X, El Yacoubi M, et al
Science 2006 Jan;311(5757):77-80
Diverse psychotomimetics act through a common signaling pathway.
Svenningsson P, Tzavara ET, Carruthers R, Rachleff I, Wattler S, Nehls M, et al
Science 2003 Nov;302(5649):1412-5